Study of hetrombopag to prevent low blood platelets from ADC therapy in breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a drug called hetrombopag to see if it can help prevent a drop in blood platelets (cells that help blood clot) caused by antibody-drug conjugate (ADC) cancer therapy. It may help patients who have already had low platelets from their treatment or are about to start an ADC regimen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with breast cancer (by biopsy or cytology).
- You are either about to start ADC treatment (a type of targeted chemo), or you had ADC treatment in your last cycle and your platelet count was below 75,000 (a measure of low platelets).
- Your doctor expects you to live at least 12 weeks and you feel well enough (ECOG score 0–2).
- Your liver and kidney function tests are within acceptable ranges, and you are not currently taking certain other drugs (like pyrotinib or CDK4/6 inhibitors).
- You have not had major bleeding, blood clots, or certain heart problems recently, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called hetrombopag that helps raise platelet counts in people with nasopharyngeal cancer who get low platelets from their chemotherapy. It may reduce the need for platelet transfusions and help you stay on your chemo schedule.
This trial tests whether a drug called hetrombopag can prevent dangerously low platelet counts (cells that help blood clot) in breast cancer patients receiving chemotherapy. It is for people who experienced very low platelets from a previous round of treatment.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
This study tests a medicine called hetrombopag that may help raise your platelet count after chemotherapy for advanced lung cancer. It aims to prevent dangerously low platelet levels so you can continue your cancer treatment more safely.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
Hear when a new CTIT-Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.